Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Miller

Showing results (171-180 of 215) with videos related to

Pageof 22
Sort By:
Archives of Neurology|January 16, 2008
Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosisElliot M Frohman, Fiona Costello, Olaf Stüve, et al.
Scientific Reports|October 28, 2016
Fully automated grey and white matter spinal cord segmentationFerran Prados, M Jorge Cardoso, Marios C Yiannakas, et al.
Annals of Neurology|February 27, 2010
Neuroplasticity predicts outcome of optic neuritis independent of tissue damageThomas M Jenkins, Ahmed T Toosy, Olga Ciccarelli, et al.
Archives of Neurology|November 11, 2009
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT studyBastiaan Moraal, Christoph Pohl, Bernard M J Uitdehaag, et al.
The New England Journal of Medicine|January 3, 2003
A controlled trial of natalizumab for relapsing multiple sclerosisDavid H Miller, Omar A Khan, William A Sheremata, et al.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 15, 2012
Diffusion MRI-based cortical complexity alterations associated with executive function in multiple sclerosisNils Muhlert, Varun Sethi, Torben Schneider, et al.
Lancet (London, England)|August 7, 2007
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
Neurology|October 11, 2015
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITKassandra L Munger, Kathryn C Fitzgerald, Mark S Freedman, et al.
Pageof 22

Showing results (171-180 of 215) with videos related to

Sort By:
Pageof 22
Archives of Neurology|January 16, 2008
Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosisElliot M Frohman, Fiona Costello, Olaf Stüve, et al.
Scientific Reports|October 28, 2016
Fully automated grey and white matter spinal cord segmentationFerran Prados, M Jorge Cardoso, Marios C Yiannakas, et al.
Annals of Neurology|February 27, 2010
Neuroplasticity predicts outcome of optic neuritis independent of tissue damageThomas M Jenkins, Ahmed T Toosy, Olga Ciccarelli, et al.
Archives of Neurology|November 11, 2009
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT studyBastiaan Moraal, Christoph Pohl, Bernard M J Uitdehaag, et al.
The New England Journal of Medicine|January 3, 2003
A controlled trial of natalizumab for relapsing multiple sclerosisDavid H Miller, Omar A Khan, William A Sheremata, et al.
The Lancet. Neurology|September 15, 2009
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 15, 2012
Diffusion MRI-based cortical complexity alterations associated with executive function in multiple sclerosisNils Muhlert, Varun Sethi, Torben Schneider, et al.
Lancet (London, England)|August 7, 2007
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
Neurology|October 11, 2015
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITKassandra L Munger, Kathryn C Fitzgerald, Mark S Freedman, et al.
Pageof 22